46 related articles for article (PubMed ID: 16709188)
21. Heparan sulfate mimicry: a synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity.
Sarrazin S; Bonnaffé D; Lubineau A; Lortat-Jacob H
J Biol Chem; 2005 Nov; 280(45):37558-64. PubMed ID: 16155294
[TBL] [Abstract][Full Text] [Related]
22. Molecular organization of the interferon gamma-binding domain in heparan sulphate.
Lortat-Jacob H; Turnbull JE; Grimaud JA
Biochem J; 1995 Sep; 310 ( Pt 2)(Pt 2):497-505. PubMed ID: 7654188
[TBL] [Abstract][Full Text] [Related]
23. Non-receptor-mediated tissue localization of human interferon-gamma: role of heparan sulfate/heparin-like molecules.
Lortat-Jacob H; Brisson C; Guerret S; Morel G
Cytokine; 1996 Jul; 8(7):557-66. PubMed ID: 8891437
[TBL] [Abstract][Full Text] [Related]
24. The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation.
Sadir R; Forest E; Lortat-Jacob H
J Biol Chem; 1998 May; 273(18):10919-25. PubMed ID: 9556569
[TBL] [Abstract][Full Text] [Related]
25. Interferon and heparan sulphate.
Lortat-Jacob H
Biochem Soc Trans; 2006 Jun; 34(Pt 3):461-4. PubMed ID: 16709188
[TBL] [Abstract][Full Text] [Related]
26. Gamma interferon signaling: insights to development of interferon mimetics.
Johnson HM; Ahmed CM
Cell Mol Biol (Noisy-le-grand); 2006 May; 52(1):71-6. PubMed ID: 16914098
[TBL] [Abstract][Full Text] [Related]
27. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
28. Structural analysis of IL-10 and Type I interferon family members and their complexes with receptor.
Walter MR
Adv Protein Chem; 2004; 68():171-223. PubMed ID: 15500862
[No Abstract] [Full Text] [Related]
29. Multiprotein signalling complexes: regional assembly on heparan sulphate.
Gallagher JT
Biochem Soc Trans; 2006 Jun; 34(Pt 3):438-41. PubMed ID: 16709181
[TBL] [Abstract][Full Text] [Related]
30. Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity.
Lortat-Jacob H; Grimaud JA
Cell Mol Biol; 1991; 37(3):253-60. PubMed ID: 1934005
[TBL] [Abstract][Full Text] [Related]
31. The role of heparin/heparan sulphate in the IFN-γ-led Arena.
Xu K; Jin L
Biochimie; 2020 Mar; 170():1-9. PubMed ID: 31794784
[TBL] [Abstract][Full Text] [Related]
32. Interferon-gamma, an anti-fibrogenic cytokine which binds to heparan sulfate.
Lortat-Jacob H; Esterre P; Grimaud JA
Pathol Res Pract; 1994 Oct; 190(9-10):920-2. PubMed ID: 7899141
[TBL] [Abstract][Full Text] [Related]
33. The yin and yang of type I interferon activity in bacterial infection.
Decker T; Müller M; Stockinger S
Nat Rev Immunol; 2005 Sep; 5(9):675-87. PubMed ID: 16110316
[TBL] [Abstract][Full Text] [Related]
34. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
[TBL] [Abstract][Full Text] [Related]
35. Tinkering with heparan sulfate sulfation to steer development.
Gorsi B; Stringer SE
Trends Cell Biol; 2007 Apr; 17(4):173-7. PubMed ID: 17320398
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology of heparan sulphate: many diseases, few drugs.
Lindahl U; Kjellén L
J Intern Med; 2013 Jun; 273(6):555-71. PubMed ID: 23432337
[TBL] [Abstract][Full Text] [Related]
37. Cytokine signalling in the beta-cell: a dual role for IFNgamma.
Gysemans C; Callewaert H; Overbergh L; Mathieu C
Biochem Soc Trans; 2008 Jun; 36(Pt 3):328-33. PubMed ID: 18481951
[TBL] [Abstract][Full Text] [Related]
38. [Structure and biologic function of IFNgamma].
Nammous AH; Pietruczuk M; Zubacki D; Dobrzycki I
Przegl Lek; 2005; 62(9):890-3. PubMed ID: 16541724
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
